Rinath Malka Jeselsohn, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Estrogen Receptor alpha | 15 | 2024 | 581 | 3.610 |
Why?
|
Receptors, Estrogen | 25 | 2024 | 2253 | 3.220 |
Why?
|
Breast Neoplasms | 49 | 2024 | 21206 | 2.630 |
Why?
|
Drug Resistance, Neoplasm | 17 | 2024 | 5341 | 1.590 |
Why?
|
Selective Estrogen Receptor Modulators | 5 | 2022 | 131 | 1.580 |
Why?
|
Antineoplastic Agents, Hormonal | 11 | 2024 | 1536 | 1.520 |
Why?
|
Cyclin-Dependent Kinases | 2 | 2024 | 663 | 0.750 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2024 | 998 | 0.740 |
Why?
|
Carcinoma, Lobular | 2 | 2022 | 480 | 0.720 |
Why?
|
Receptor, erbB-2 | 8 | 2024 | 2603 | 0.690 |
Why?
|
Tamoxifen | 9 | 2022 | 966 | 0.650 |
Why?
|
Carcinoma, Ductal, Breast | 3 | 2022 | 1099 | 0.640 |
Why?
|
Cell Cycle | 3 | 2024 | 2932 | 0.640 |
Why?
|
Protein Kinase Inhibitors | 3 | 2024 | 5703 | 0.580 |
Why?
|
Immune Complex Diseases | 1 | 2016 | 50 | 0.550 |
Why?
|
Estradiol | 6 | 2019 | 1951 | 0.550 |
Why?
|
SOX9 Transcription Factor | 1 | 2017 | 145 | 0.530 |
Why?
|
Cyclin-Dependent Kinase 4 | 4 | 2024 | 565 | 0.500 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2018 | 410 | 0.500 |
Why?
|
Mutation | 14 | 2024 | 30238 | 0.490 |
Why?
|
NF-kappa B | 1 | 2023 | 2493 | 0.480 |
Why?
|
Antigen-Antibody Complex | 1 | 2016 | 513 | 0.480 |
Why?
|
Glomerulonephritis | 1 | 2016 | 333 | 0.470 |
Why?
|
Aromatase Inhibitors | 4 | 2024 | 519 | 0.440 |
Why?
|
Chromatin | 4 | 2022 | 2981 | 0.430 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2016 | 622 | 0.410 |
Why?
|
Apoptosis | 5 | 2024 | 9523 | 0.410 |
Why?
|
Mammary Glands, Animal | 2 | 2012 | 273 | 0.390 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1744 | 0.380 |
Why?
|
Cyclin D1 | 2 | 2012 | 453 | 0.380 |
Why?
|
Estrogens | 6 | 2023 | 1536 | 0.340 |
Why?
|
Paclitaxel | 1 | 2016 | 1733 | 0.320 |
Why?
|
Proto-Oncogene Proteins | 1 | 2021 | 4528 | 0.320 |
Why?
|
Cell Proliferation | 12 | 2024 | 10474 | 0.310 |
Why?
|
Neoplasm Proteins | 3 | 2018 | 3603 | 0.310 |
Why?
|
Indoles | 4 | 2022 | 1836 | 0.310 |
Why?
|
Ligands | 4 | 2022 | 3284 | 0.290 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 3 | 2016 | 165 | 0.280 |
Why?
|
Female | 49 | 2024 | 397192 | 0.280 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2010 | 506 | 0.280 |
Why?
|
Alleles | 1 | 2018 | 6894 | 0.270 |
Why?
|
Signal Transduction | 7 | 2024 | 23645 | 0.270 |
Why?
|
Piperazines | 4 | 2021 | 2554 | 0.260 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2024 | 8647 | 0.250 |
Why?
|
Gene Expression | 2 | 2021 | 7598 | 0.250 |
Why?
|
Estrogen Antagonists | 2 | 2023 | 151 | 0.250 |
Why?
|
Pyridines | 4 | 2021 | 2894 | 0.230 |
Why?
|
Cell Line, Tumor | 10 | 2024 | 17140 | 0.230 |
Why?
|
Humans | 54 | 2024 | 768166 | 0.220 |
Why?
|
Osteopontin | 1 | 2024 | 306 | 0.210 |
Why?
|
Starfish | 1 | 2022 | 13 | 0.200 |
Why?
|
Acupuncture, Ear | 1 | 2022 | 13 | 0.200 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 11878 | 0.200 |
Why?
|
Neoplasm Metastasis | 4 | 2021 | 4912 | 0.190 |
Why?
|
Histone Acetyltransferases | 1 | 2023 | 335 | 0.190 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2024 | 3611 | 0.190 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 3948 | 0.180 |
Why?
|
Antigen Presentation | 2 | 2023 | 1251 | 0.180 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2021 | 317 | 0.180 |
Why?
|
Aminopyridines | 1 | 2024 | 580 | 0.180 |
Why?
|
Ketones | 1 | 2021 | 183 | 0.180 |
Why?
|
Furans | 1 | 2021 | 199 | 0.170 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2017 | 952 | 0.160 |
Why?
|
Benzimidazoles | 1 | 2024 | 864 | 0.160 |
Why?
|
Retinoblastoma-Binding Protein 2 | 1 | 2018 | 35 | 0.160 |
Why?
|
Cinnamates | 1 | 2018 | 59 | 0.160 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2023 | 1151 | 0.150 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 354 | 0.150 |
Why?
|
Jumonji Domain-Containing Histone Demethylases | 1 | 2018 | 168 | 0.150 |
Why?
|
Prognosis | 9 | 2024 | 30010 | 0.150 |
Why?
|
Mitochondrial Proteins | 1 | 2023 | 979 | 0.140 |
Why?
|
Gene Expression Profiling | 6 | 2021 | 9538 | 0.140 |
Why?
|
Mouth Neoplasms | 1 | 2022 | 597 | 0.140 |
Why?
|
Workflow | 2 | 2021 | 860 | 0.140 |
Why?
|
Stem Cells | 1 | 2010 | 3537 | 0.140 |
Why?
|
Transcription Factor AP-2 | 1 | 2016 | 78 | 0.130 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3671 | 0.130 |
Why?
|
Embryo, Mammalian | 1 | 2021 | 1676 | 0.120 |
Why?
|
Transcription Factor AP-1 | 1 | 2016 | 321 | 0.120 |
Why?
|
Adaptation, Physiological | 1 | 2021 | 1312 | 0.110 |
Why?
|
Cell Differentiation | 2 | 2019 | 11669 | 0.110 |
Why?
|
Interleukin-8 | 1 | 2016 | 704 | 0.110 |
Why?
|
Epidermal Growth Factor | 1 | 2016 | 697 | 0.110 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2892 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 948 | 0.100 |
Why?
|
Breast | 2 | 2022 | 1976 | 0.100 |
Why?
|
Drug Resistance | 1 | 2018 | 1599 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2013 | 313 | 0.100 |
Why?
|
Tumor Cells, Cultured | 4 | 2021 | 6124 | 0.100 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2017 | 757 | 0.100 |
Why?
|
Mice | 10 | 2024 | 82029 | 0.090 |
Why?
|
Animals | 13 | 2024 | 169246 | 0.090 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11244 | 0.090 |
Why?
|
Antineoplastic Agents | 3 | 2022 | 13676 | 0.090 |
Why?
|
Sequence Analysis, RNA | 1 | 2018 | 2040 | 0.090 |
Why?
|
Viral Core Proteins | 1 | 2010 | 158 | 0.080 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6847 | 0.080 |
Why?
|
Antigens, Viral, Tumor | 1 | 2010 | 153 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2019 | 2846 | 0.080 |
Why?
|
Computational Biology | 1 | 2021 | 3568 | 0.080 |
Why?
|
Gene Knock-In Techniques | 1 | 2010 | 422 | 0.080 |
Why?
|
Bone Neoplasms | 1 | 2020 | 2565 | 0.070 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1135 | 0.070 |
Why?
|
Epithelium | 1 | 2012 | 1607 | 0.070 |
Why?
|
Repressor Proteins | 1 | 2018 | 2982 | 0.070 |
Why?
|
GATA3 Transcription Factor | 2 | 2022 | 163 | 0.070 |
Why?
|
Mice, Transgenic | 2 | 2018 | 9561 | 0.070 |
Why?
|
Transcription Factors | 3 | 2022 | 12168 | 0.070 |
Why?
|
Postmenopause | 1 | 2016 | 2518 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2015 | 4120 | 0.070 |
Why?
|
Genetic Heterogeneity | 2 | 2021 | 736 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9419 | 0.060 |
Why?
|
Administration, Oral | 2 | 2024 | 4030 | 0.060 |
Why?
|
Receptors, Progesterone | 2 | 2021 | 1160 | 0.060 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 2474 | 0.060 |
Why?
|
Autophagy | 1 | 2012 | 1349 | 0.060 |
Why?
|
Mutation, Missense | 1 | 2013 | 2592 | 0.060 |
Why?
|
Epigenesis, Genetic | 1 | 2017 | 3833 | 0.060 |
Why?
|
Nuclear Proteins | 1 | 2018 | 5804 | 0.060 |
Why?
|
Software | 1 | 2018 | 4478 | 0.060 |
Why?
|
Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2023 | 53 | 0.060 |
Why?
|
Neoplasms | 2 | 2022 | 22371 | 0.050 |
Why?
|
Mice, Nude | 2 | 2020 | 3623 | 0.050 |
Why?
|
Double-Blind Method | 1 | 2016 | 12465 | 0.050 |
Why?
|
Cyclin-Dependent Kinase 9 | 1 | 2021 | 68 | 0.050 |
Why?
|
Interleukin-4 | 1 | 2024 | 1156 | 0.040 |
Why?
|
Up-Regulation | 2 | 2021 | 4146 | 0.040 |
Why?
|
Middle Aged | 7 | 2024 | 223492 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 362 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2022 | 5315 | 0.040 |
Why?
|
Flow Cytometry | 1 | 2010 | 5902 | 0.040 |
Why?
|
Nausea | 1 | 2022 | 682 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2022 | 65371 | 0.040 |
Why?
|
Estrogen Receptor Modulators | 1 | 2018 | 58 | 0.040 |
Why?
|
Vomiting | 1 | 2022 | 655 | 0.040 |
Why?
|
Camptothecin | 1 | 2022 | 600 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2024 | 59629 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11101 | 0.040 |
Why?
|
p21-Activated Kinases | 1 | 2018 | 127 | 0.040 |
Why?
|
Protein Binding | 2 | 2020 | 9343 | 0.030 |
Why?
|
Thiazoles | 1 | 2024 | 1542 | 0.030 |
Why?
|
Mutant Proteins | 1 | 2018 | 488 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5926 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2010 | 11095 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12840 | 0.030 |
Why?
|
Protein Structure, Secondary | 1 | 2018 | 1216 | 0.030 |
Why?
|
src-Family Kinases | 1 | 2018 | 539 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1105 | 0.030 |
Why?
|
Promoter Regions, Genetic | 2 | 2017 | 5797 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2359 | 0.030 |
Why?
|
Transcription, Genetic | 2 | 2021 | 7608 | 0.030 |
Why?
|
Adult | 5 | 2024 | 223646 | 0.030 |
Why?
|
Epithelial Cells | 2 | 2019 | 3703 | 0.030 |
Why?
|
Immunoconjugates | 1 | 2022 | 975 | 0.030 |
Why?
|
Sequence Alignment | 1 | 2018 | 2179 | 0.030 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2018 | 1169 | 0.030 |
Why?
|
Aged | 4 | 2024 | 171504 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2018 | 3055 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2024 | 2830 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2023 | 2954 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2023 | 3728 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2885 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2021 | 2048 | 0.030 |
Why?
|
Genes, erbB-2 | 1 | 2012 | 162 | 0.020 |
Why?
|
Exercise Therapy | 1 | 2019 | 939 | 0.020 |
Why?
|
Peptides | 1 | 2024 | 4354 | 0.020 |
Why?
|
Drug Synergism | 1 | 2016 | 1760 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2021 | 4283 | 0.020 |
Why?
|
Biopsy | 1 | 2023 | 6793 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 40218 | 0.020 |
Why?
|
Aspartic Acid | 1 | 2013 | 577 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2019 | 3620 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2018 | 2732 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3556 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2022 | 2907 | 0.020 |
Why?
|
Down-Regulation | 1 | 2018 | 2937 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2021 | 4786 | 0.020 |
Why?
|
Glycine | 1 | 2013 | 672 | 0.020 |
Why?
|
Preoperative Care | 1 | 2019 | 2258 | 0.020 |
Why?
|
Macrophages | 1 | 2024 | 5799 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2013 | 1743 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4446 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2012 | 1837 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4755 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3428 | 0.020 |
Why?
|
Mice, SCID | 1 | 2012 | 2627 | 0.020 |
Why?
|
Base Sequence | 1 | 2018 | 12421 | 0.020 |
Why?
|
Cell Line | 1 | 2021 | 15597 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7453 | 0.020 |
Why?
|
Survival Analysis | 1 | 2016 | 10101 | 0.010 |
Why?
|
DNA Methylation | 1 | 2017 | 4428 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2018 | 12800 | 0.010 |
Why?
|
Exercise | 1 | 2019 | 5955 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9615 | 0.010 |
Why?
|
Cohort Studies | 1 | 2022 | 41754 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2017 | 39348 | 0.010 |
Why?
|
Young Adult | 1 | 2022 | 60066 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18349 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2012 | 22379 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2015 | 13586 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2018 | 81762 | 0.010 |
Why?
|
Male | 1 | 2020 | 364719 | 0.000 |
Why?
|